MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Amgen Inc

Open

SectorHealthcare

295.34 0.37

Overview

Share price change

24h

Current

Min

293.54

Max

297.54

Key metrics

By Trading Economics

Income

-298M

1.4B

Sales

1B

9.2B

P/E

Sector Avg

22.328

35.739

EPS

6.02

Dividend yield

3.39

Profit margin

15.621

Employees

28,000

EBITDA

2.4B

3.6B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+9.29% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.39%

3.08%

Next Earnings

4 Nov 2025

Next Dividend date

8 Dec 2025

Next Ex Dividend date

17 Nov 2025

Market Stats

By TradingEconomics

Market Cap

-15B

147B

Previous open

294.97

Previous close

295.34

News Sentiment

By Acuity

41%

59%

164 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Amgen Inc Chart

Past performance is not a reliable indicator of future results.

Related News

5 Aug 2025, 20:51 UTC

Earnings

Amgen Posts Higher 2Q Profit, Revenue On Sales Growth Among Products

23 Jun 2025, 19:24 UTC

Major Market Movers

Amgen Expands MariTide Development Plans After Weight-Loss Trial -- Update

23 Jun 2025, 19:07 UTC

Major Market Movers

Amgen Expands MariTide Development Plans After Successful Weight-Loss Trial

1 May 2025, 20:17 UTC

Earnings

Amgen 1Q Revenue Up 9% as Many Products Deliver Double-Digit Sales Growth

5 Aug 2025, 20:01 UTC

Earnings

Amgen Sees FY Rev $35B-$36B >AMGN

5 Aug 2025, 20:01 UTC

Earnings

Amgen Sees FY EPS $10.97-EPS $12.11 >AMGN

5 Aug 2025, 20:01 UTC

Earnings

Amgen Sees FY Adj EPS $20.20-Adj EPS $21.30 >AMGN

5 Aug 2025, 20:01 UTC

Earnings

Amgen 2Q Worldwide Prolia Sales $1.12B >AMGN

5 Aug 2025, 20:01 UTC

Earnings

Amgen 2Q Worldwide XGEVA Sales $532M >AMGN

5 Aug 2025, 20:01 UTC

Earnings

Amgen 2Q Net $1.43B >AMGN

5 Aug 2025, 20:01 UTC

Earnings

Amgen 2Q Worldwide Enbrel Sales $604M >AMGN

5 Aug 2025, 20:01 UTC

Earnings

Amgen 2Q Worldwide Neulasta Sales $82M >AMGN

5 Aug 2025, 20:01 UTC

Earnings

Amgen 2Q Rev $9.2B >AMGN

5 Aug 2025, 20:01 UTC

Earnings

Amgen 2Q Adj EPS $6.02 >AMGN

5 Aug 2025, 20:01 UTC

Earnings

Amgen 2Q EPS $2.65 >AMGN

28 May 2025, 18:09 UTC

Earnings

Heart Disease Could Be a Goner When These New -2-

28 May 2025, 18:09 UTC

Earnings

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

19 May 2025, 16:13 UTC

Acquisitions, Mergers, Takeovers

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

1 May 2025, 20:01 UTC

Earnings

Amgen: FY25 Share Repurchases Not to Exceed $500M

1 May 2025, 20:01 UTC

Earnings

Amgen: Guidance Includes Estimated Impact of Implemented Tariffs>AMGN

1 May 2025, 20:01 UTC

Earnings

Amgen Sees FY25 Capital Expenditures About $2.3B

1 May 2025, 20:01 UTC

Earnings

Amgen: Guidance Doesn't Account for Any Tariffs That Could Be Implemented in Future, Including Sector-specific Tariffs

1 May 2025, 20:01 UTC

Earnings

Amgen 1Q Repatha Sales $656M >AMGN

1 May 2025, 20:01 UTC

Earnings

Amgen 1Q EVENITY Sales $442M >AMGN

1 May 2025, 20:01 UTC

Earnings

Amgen 1Q Worldwide Neulasta Sales $129M >AMGN

1 May 2025, 20:01 UTC

Earnings

Amgen Sees FY25 Adj EPS $20-Adj EPS $21.20 >AMGN

1 May 2025, 20:01 UTC

Earnings

Amgen 1Q Net $1.73B >AMGN

1 May 2025, 20:01 UTC

Earnings

Amgen Sees FY25 EPS $12.21-EPS $13.46 >AMGN

1 May 2025, 20:01 UTC

Earnings

Amgen 1Q Adj EPS $4.90 >AMGN

1 May 2025, 20:01 UTC

Earnings

Amgen Sees FY25 Rev $34.3B-$35.7B >AMGN

Peer Comparison

Price change

Amgen Inc Forecast

Price Target

By TipRanks

9.29% upside

12 Months Forecast

Average 323 USD  9.29%

High 405 USD

Low 272 USD

Based on 21 Wall Street analysts offering 12 month price targets forAmgen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

21 ratings

9

Buy

11

Hold

1

Sell

Technical Score

By Trading Central

270.44 / 276.44Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

164 / 371 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
help-icon Live chat